Digital Trials Digest, our quarterly newsletter
A quarterly look at what's new in ObvioGo, where decentralized trials are heading, and the partnerships shaping what's next — new Image Capture & Central Rating features, caregiver-collected growth data research, and what's coming in OG-2.10.
Issue 2: new Assent & Countersignature capabilities, ObvioGo's direct integration with Oracle Health and Life Sciences, Novotech's multi-trial licensing agreement, and SCOPE 2026 takeaways.
Issue 1: ObvioGo's new built-in eSignature, the Template Library and Out-of-Window Data Submissions features, caregiver-centric eDiary design, and how MiHelper accelerated a decentralized migraine study.
Expectations for the time it takes to complete a vaccine clinical trial have been radically raised by the mRNA vaccines’ successes.
Decentralized trials (DCTs) expand older adults’ access to trials, allowing them to participate at higher rates.
Digital transformation is reshaping nearly every industry, and clinical trials are no exception. As technology plays a bigger role in healthcare, patients are demanding more access to medical research. It’s not just patients who are asking for more: Medical professionals, researchers, and pharmaceutical companies all want to improve quality, efficiency, and access to clinical trials.
The use of real world data in clinical trials is a hot topic. Doctors, biotech and pharmaceutical companies alike point to the tremendous potential to leverage this data to improve health outcomes.
Virtual clinical trials aren’t just a buzzword—these research models are here to stay. In fact, the global market for virtual clinical trials is expected to reach $12.9 billion by 2030, according to Grand View Research.